Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
Here's the last portion of Dr. Socinski's presentation, which covers two important trials in small cell lung cancer (SCLC) presented at ASCO 2012. The first was a SWOG trial of the standard second line agent topotecan (here given on a weekly schedule) either alone or combined with the antiangiogenic agent Eylea (aflibercept). The results of this trial were generally considered encouraging enough to warrant further study, and you can learn the details from his talk.
He also covers an important study done by the Japanese Cooperative Oncology Group (JCOG), which compared cisplatin/amrubicin to cisplatin/irinotecan, which is standard first line therapy for extensive stage SCLC in Japan. Dr. Socinski reviews the results and places them in context for us.
Below is the video and audio versions of the podcast, along with the transcript and figures.
Dr. Socinski ASCO LC Highlights 2012 SCLC Update Audio Podcast
Dr. Socinski ASCO LC Highlights 2012 SCLC Update Transcript
Dr. Socinski ASCO LC Highlights 2012 SCLC Update Figs
We'll have Dr. Joel Neal's coverage of several novel agents for lung cancer that showed promise at ASCO 2012 in the next series of podcasts. Look for those soon.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi amitchouhan,
Welcome to Grace. At this time, there aren't any targeted therapies to treat SCLC, but there are new treatments. Check out our latest OncTalk webinar from December. The last...
I was searching for this, Thank you so much for the info.